Skip to main content
Top
Published in: Journal of Nuclear Cardiology 3/2019

01-06-2019 | Theme Article

My warranty has expired: I need to be retested

Authors: Mario Petretta, MD, Wanda Acampa, MD, PhD, Roberta Assante, MD, PhD, Emilia Zampella, MD, PhD, Carmela Nappi, MD, Andrea Petretta, MD, PhD, Alberto Cuocolo, MD

Published in: Journal of Nuclear Cardiology | Issue 3/2019

Login to get access

Abstract

The concept of warranty period, the duration of time during which the patient’s risk remains low, is appealing. However, some points remain to be resolved before its translation in the clinical arena. Methodological issues should be standardized in order to compare the results of studies in different patient populations. Also, the definition of a “normal” study should always take into consideration the history of prior revascularization, the achieved level of exercise, and the stressor used. The promise of warranty can be questioned by the patient’s baseline demographic and clinical characteristics and may also be influenced by life-style modification in the course of the follow-up. The “warranty period” concept should shift from data reflecting the time to a cardiac event to the development of ischemia, given an opportunity for intervention before a cardiac event occurs. In this context, clarify the role of serial imaging can be extremely useful, in particular to evaluate if and when retesting a patient after a normal scan.
Appendix
Available only for authorised users
Literature
1.
go back to reference Blischke WR, Karim MR, Murthy DNP. An overview. Warranty data collection and analysis. In: Springer series in reliability engineering. London: Springer; 2011. p. 1-15. Blischke WR, Karim MR, Murthy DNP. An overview. Warranty data collection and analysis. In: Springer series in reliability engineering. London: Springer; 2011. p. 1-15.
2.
go back to reference Hachamovitch R, Berman D, Kiat H, Cohen I, Cabico A, Diamond G. What is the warranty for normal exercise sestamibi SPECT? Circulation 1995;92(8):2491. Hachamovitch R, Berman D, Kiat H, Cohen I, Cabico A, Diamond G. What is the warranty for normal exercise sestamibi SPECT? Circulation 1995;92(8):2491.
3.
go back to reference Schinkel AF, Elhendy A, Van Domburg RT, Bax JJ, Valkema R, Roelandt JR, et al. Long-term prognostic value of dobutamine stress 99mTc-sestamibi SPECT: single-center experience with 8-year follow-up. Radiology 2002;225:701-6.CrossRefPubMed Schinkel AF, Elhendy A, Van Domburg RT, Bax JJ, Valkema R, Roelandt JR, et al. Long-term prognostic value of dobutamine stress 99mTc-sestamibi SPECT: single-center experience with 8-year follow-up. Radiology 2002;225:701-6.CrossRefPubMed
4.
go back to reference Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.CrossRefPubMed Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.CrossRefPubMed
5.
go back to reference Hachamovitch R, Hayes S, Friedman JD, Cohen I, Shaw LJ, Germano G, et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans: what is the warranty period of a normal scan? J Am Coll Cardiol 2003;41:1329-40.CrossRefPubMed Hachamovitch R, Hayes S, Friedman JD, Cohen I, Shaw LJ, Germano G, et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans: what is the warranty period of a normal scan? J Am Coll Cardiol 2003;41:1329-40.CrossRefPubMed
6.
go back to reference Rozanski A, Gransar H, Min JK, Hayes SW, Friedman JD, Thomson LE, et al. Long-term mortality following normal exercise myocardial perfusion SPECT according to coronary disease risk factors. J Nucl Cardiol 2014;21:341-50.CrossRefPubMed Rozanski A, Gransar H, Min JK, Hayes SW, Friedman JD, Thomson LE, et al. Long-term mortality following normal exercise myocardial perfusion SPECT according to coronary disease risk factors. J Nucl Cardiol 2014;21:341-50.CrossRefPubMed
7.
go back to reference Ottenhof MJ, Wai MC, Boiten HJ, Korbee RS, Valkema R, van Domburg RT, et al. 12-Year outcome after normal myocardial perfusion SPECT in patients with known coronary artery disease. J Nucl Cardiol 2013;20:748-54.CrossRefPubMed Ottenhof MJ, Wai MC, Boiten HJ, Korbee RS, Valkema R, van Domburg RT, et al. 12-Year outcome after normal myocardial perfusion SPECT in patients with known coronary artery disease. J Nucl Cardiol 2013;20:748-54.CrossRefPubMed
8.
go back to reference Nakanishi R, Gransar H, Slomka P, Arsanjani R, Shalev A, Otaki Y, et al. Predictors of high-risk coronary artery disease in subjects with normal SPECT myocardial perfusion imaging. J Nucl Cardiol 2016;23:530-41.CrossRefPubMed Nakanishi R, Gransar H, Slomka P, Arsanjani R, Shalev A, Otaki Y, et al. Predictors of high-risk coronary artery disease in subjects with normal SPECT myocardial perfusion imaging. J Nucl Cardiol 2016;23:530-41.CrossRefPubMed
9.
go back to reference Elhendy A, Schinkel A, Bax JJ, van Domburg RT, Poldermans D. Long-term prognosis after a normal exercise stress Tc-99m sestamibi SPECT study. J Nucl Cardiol 2003;10:261-6.CrossRefPubMed Elhendy A, Schinkel A, Bax JJ, van Domburg RT, Poldermans D. Long-term prognosis after a normal exercise stress Tc-99m sestamibi SPECT study. J Nucl Cardiol 2003;10:261-6.CrossRefPubMed
10.
go back to reference Acampa W, Evangelista L, Petretta M, Liuzzi R, Cuocolo A. Usefulness of stress cardiac single-photon emission computed tomographic imaging late after percutaneous coronary intervention for assessing cardiac events and time to such events. Am J Cardiol 2007;100:436-41.CrossRefPubMed Acampa W, Evangelista L, Petretta M, Liuzzi R, Cuocolo A. Usefulness of stress cardiac single-photon emission computed tomographic imaging late after percutaneous coronary intervention for assessing cardiac events and time to such events. Am J Cardiol 2007;100:436-41.CrossRefPubMed
11.
go back to reference Carryer DJ, Askew JW, Hodge DO, Miller TD, Gibbons RJ. The timing and impact of follow-up studies after normal stress single-photon emission computed tomography sestamibi studies. Circ Cardiovasc Imaging 2010;3:520-6.CrossRefPubMed Carryer DJ, Askew JW, Hodge DO, Miller TD, Gibbons RJ. The timing and impact of follow-up studies after normal stress single-photon emission computed tomography sestamibi studies. Circ Cardiovasc Imaging 2010;3:520-6.CrossRefPubMed
12.
go back to reference Schinkel AF, Boiten HJ, van der Sijde JN, Ruitinga PR, Sijbrands EJ, Valkema R, et al. 15-Year outcome after normal exercise Tc-99m sestamibi myocardial perfusion imaging: what is the duration of low risk after a normal scan? J Nucl Cardiol 2012;19:901-6.CrossRefPubMedPubMedCentral Schinkel AF, Boiten HJ, van der Sijde JN, Ruitinga PR, Sijbrands EJ, Valkema R, et al. 15-Year outcome after normal exercise Tc-99m sestamibi myocardial perfusion imaging: what is the duration of low risk after a normal scan? J Nucl Cardiol 2012;19:901-6.CrossRefPubMedPubMedCentral
13.
go back to reference Simonsen JA, Gerke O, Rask CK, Tamadoni M, Thomassen A, Hess S, et al. Prognosis in patients with suspected or known ischemic heart disease and normal myocardial perfusion: long-term outcome and temporal risk variations. J Nucl Cardiol 2013;20:347-57.CrossRefPubMed Simonsen JA, Gerke O, Rask CK, Tamadoni M, Thomassen A, Hess S, et al. Prognosis in patients with suspected or known ischemic heart disease and normal myocardial perfusion: long-term outcome and temporal risk variations. J Nucl Cardiol 2013;20:347-57.CrossRefPubMed
14.
go back to reference Acampa W, Petretta M, Cuocolo R, Daniele S, Cantoni V, Cuocolo A. Warranty period of normal stress myocardial perfusion imaging in diabetic patients: a propensity score analysis. J Nucl Cardiol 2014;21:50-6.CrossRefPubMed Acampa W, Petretta M, Cuocolo R, Daniele S, Cantoni V, Cuocolo A. Warranty period of normal stress myocardial perfusion imaging in diabetic patients: a propensity score analysis. J Nucl Cardiol 2014;21:50-6.CrossRefPubMed
15.
go back to reference Nudi F, Neri G, Schillaci O, Pinto A, Procaccini E, Vetere M, et al. Time to and risk of cardiac events after myocardial perfusion scintigraphy. J Cardiol 2015;66:125-9.CrossRefPubMed Nudi F, Neri G, Schillaci O, Pinto A, Procaccini E, Vetere M, et al. Time to and risk of cardiac events after myocardial perfusion scintigraphy. J Cardiol 2015;66:125-9.CrossRefPubMed
16.
go back to reference Romero-Farina G, Candell-Riera J, Aguadé-Bruix S, Ferreira-González I, Cuberas-Borrós G, Pizzi N, et al. Warranty periods for normal myocardial perfusion stress SPECT. J Nucl Cardiol 2015;22:44-54.CrossRefPubMed Romero-Farina G, Candell-Riera J, Aguadé-Bruix S, Ferreira-González I, Cuberas-Borrós G, Pizzi N, et al. Warranty periods for normal myocardial perfusion stress SPECT. J Nucl Cardiol 2015;22:44-54.CrossRefPubMed
17.
go back to reference Navare SM, Mather JF, Shaw LJ, Fowler MS, Heller GV. Comparison of risk stratification with pharmacologic and exercise stress myocardial perfusion imaging: a meta-analysis. J Nucl Cardiol 2004;11:551-6.CrossRefPubMed Navare SM, Mather JF, Shaw LJ, Fowler MS, Heller GV. Comparison of risk stratification with pharmacologic and exercise stress myocardial perfusion imaging: a meta-analysis. J Nucl Cardiol 2004;11:551-6.CrossRefPubMed
18.
go back to reference Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
19.
go back to reference Barraclough H, Simms L, Govindan R. Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol 2011;6:978-82.CrossRefPubMed Barraclough H, Simms L, Govindan R. Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol 2011;6:978-82.CrossRefPubMed
20.
go back to reference Hagar Y, Dignam JJ, Dukic V. Flexible modeling of the hazard rate and treatment effects in long-term survival studies. Stat Methods Med Res 2017;26:2455-80.CrossRefPubMedPubMedCentral Hagar Y, Dignam JJ, Dukic V. Flexible modeling of the hazard rate and treatment effects in long-term survival studies. Stat Methods Med Res 2017;26:2455-80.CrossRefPubMedPubMedCentral
21.
go back to reference Andersen PK, Gill RD. Cox’s regression model for counting processes: a large sample study. Ann Stat 1982;10:1100-20.CrossRef Andersen PK, Gill RD. Cox’s regression model for counting processes: a large sample study. Ann Stat 1982;10:1100-20.CrossRef
22.
24.
go back to reference Weibull W. A Statistical Distribution Function of Wide Applicability. J Appl Mech 1951;18:293-7. Weibull W. A Statistical Distribution Function of Wide Applicability. J Appl Mech 1951;18:293-7.
25.
26.
go back to reference van Houwelingen HC, Putter H. Dynamic prediction in clinical survival analysis. Boca Raton: Chapman & Hall; 2011.CrossRef van Houwelingen HC, Putter H. Dynamic prediction in clinical survival analysis. Boca Raton: Chapman & Hall; 2011.CrossRef
27.
go back to reference Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modeling and estimation of treatment effects. Stat Med 2002;21:2175-97.CrossRefPubMed Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modeling and estimation of treatment effects. Stat Med 2002;21:2175-97.CrossRefPubMed
28.
go back to reference Efron B. Logistic regression, survival analysis, and the Kaplan-Meier Curve. J Am Stat Assoc 1988;83:414-25.CrossRef Efron B. Logistic regression, survival analysis, and the Kaplan-Meier Curve. J Am Stat Assoc 1988;83:414-25.CrossRef
29.
go back to reference El-Hajj S, AlJaroudi WA, Farag A, Bleich S, Manaoragada P, Iskandrian AE, et al. Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients. J Nucl Cardiol 2016;23:101-12.CrossRefPubMed El-Hajj S, AlJaroudi WA, Farag A, Bleich S, Manaoragada P, Iskandrian AE, et al. Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients. J Nucl Cardiol 2016;23:101-12.CrossRefPubMed
31.
go back to reference Asar Ö, Ritchie J, Kalra PA, Diggle PJ. Joint modeling of repeated measurement and time-to-event data: an introductory tutorial. Int J Epidemiol 2015;44:334-44.CrossRefPubMed Asar Ö, Ritchie J, Kalra PA, Diggle PJ. Joint modeling of repeated measurement and time-to-event data: an introductory tutorial. Int J Epidemiol 2015;44:334-44.CrossRefPubMed
32.
go back to reference Petretta M, Salvatore M, Cuocolo A. Immortality time and serial myocardial perfusion imaging: only those who do not die may repeat the exam. J Nucl Cardiol 2016;23:113-6.CrossRefPubMed Petretta M, Salvatore M, Cuocolo A. Immortality time and serial myocardial perfusion imaging: only those who do not die may repeat the exam. J Nucl Cardiol 2016;23:113-6.CrossRefPubMed
33.
go back to reference Rizopoulos D. JM: an R package for the joint modeling of longitudinal and time-to-event data. J Stat Soft 2010;35:1-33.CrossRef Rizopoulos D. JM: an R package for the joint modeling of longitudinal and time-to-event data. J Stat Soft 2010;35:1-33.CrossRef
34.
go back to reference Crowther MJ, Abrams KR, Lambert PC. Joint modeling of longitudinal and survival data. Stata J 2013;13:165-84.CrossRef Crowther MJ, Abrams KR, Lambert PC. Joint modeling of longitudinal and survival data. Stata J 2013;13:165-84.CrossRef
Metadata
Title
My warranty has expired: I need to be retested
Authors
Mario Petretta, MD
Wanda Acampa, MD, PhD
Roberta Assante, MD, PhD
Emilia Zampella, MD, PhD
Carmela Nappi, MD
Andrea Petretta, MD, PhD
Alberto Cuocolo, MD
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 3/2019
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-017-1154-y

Other articles of this Issue 3/2019

Journal of Nuclear Cardiology 3/2019 Go to the issue